Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Synovial 1Sarcoma 1Neurofibrosarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1

Interventions

Doxorubicin 3pembrolizumab 2Radiotherapy 2ribociclib 1peposertib 1montanide ISA 51 1liposomal doxorubicin 1itacitinib 1futibatinib 1cixutumumab 1belinostat 1baricitinib 1avelumab 1Specimen Handling 1Radiation 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Ifosfamide 1INCB039110 1Histamine H2 Antagonists 1Fluorouracil 1Famotidine 1Erlotinib Hydrochloride 1Chemotherapy, Adjuvant 1Celecoxib 1Biopsy 1BO-112 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Histiocytoma, Malignant Fibrous × BO-112 × Clear all
NCT04420975 2026-03-10

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
14 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡